Latest Breaking News On - Michael szumeraexternal communications - Page 1 : comparemela.com

FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy

FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

David deluciaMichael szumeraexternal communicationsDrug administrationFibrogen incExchange commissionNorth star ambulatory assessmentThane wettigInterim chief executive officerDuchenne muscular dystrophyOrphan drug designationFast trackRare pediatric disease designationLooking statements thisAnnual reportQuarterly reportMichael szumeraexternal

FibroGen (FGEN) Announces Topline Results from LELANTOS-2

FibroGen (FGEN) Announces Topline Results from LELANTOS-2
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

David deluciaMichael szumeraexternal communicationsFibrogen incExchange commissionDrug administrationNorth star ambulatory assessmentThane wettigInterim chief executive officerAbout duchenne muscular dystrophyOrphan drug designationFast trackRare pediatric disease designationLooking statements thisAnnual reportQuarterly reportMichael szumeraexternal